List of Excipients in Branded Drug AGGRASTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Medicure International Inc	AGGRASTAT	tirofiban	25208-002	ANHYDROUS CITRIC ACID
Medicure International Inc	AGGRASTAT	tirofiban	25208-002	SODIUM CHLORIDE
Medicure International Inc	AGGRASTAT	tirofiban	25208-002	TRISODIUM CITRATE DIHYDRATE
Medicure International Inc	AGGRASTAT	tirofiban	25208-002	WATER
Medicure International Inc	AGGRASTAT	tirofiban	25208-902	ANHYDROUS CITRIC ACID
Medicure International Inc	AGGRASTAT	tirofiban	25208-902	SODIUM CHLORIDE

AGGRASTAT Excipient Strategy and Commercial Opportunities for Tirofiban

Last updated: August 4, 2026

AGGRASTAT is an intravenous tirofiban hydrochloride product used to inhibit platelet aggregation in patients with acute coronary syndrome and during percutaneous coronary intervention. Its active pharmaceutical ingredient is off-patent, and commercial differentiation depends less on new chemical-entity exclusivity than on ready-to-use presentation, hospital workflow, stability, supply reliability, and procurement economics.

The strongest excipient opportunities are concentrated in four areas: premixed bags, concentrated dosing formats, low-particulate and container-closure performance, and differentiated regional presentations. Conventional reformulation patents may provide limited protection unless they demonstrate a measurable stability, compatibility, dosing, or manufacturing advantage.

What is AGGRASTAT and how is tirofiban formulated?

AGGRASTAT contains tirofiban hydrochloride, a small-molecule glycoprotein IIb/IIIa platelet inhibitor. The product is administered intravenously and is used with aspirin and heparin in specified acute coronary syndrome and PCI settings. The FDA-approved formulation is an aqueous, sterile, preservative-free solution. [1]

The principal excipients reported for AGGRASTAT include:

Component	Function
Sodium chloride	Isotonicity adjustment
Sodium citrate dihydrate	Buffering and pH control
Citric acid anhydrous	Buffering and pH control
Water for injection	Vehicle

The commercial product has been supplied in more than one concentration and container format, including premixed infusion presentations and higher-concentration formats intended to reduce infusion volume. Exact strengths, bag sizes, and labeling should be confirmed against the current FDA-approved label and National Drug Code records before a product-development or licensing decision. [1,2]

The formulation is intentionally simple. It does not depend on a complex solubilizer system, preservative, surfactant, or lyophilization process. That simplicity reduces formulation-development risk but also narrows the scope for composition-based differentiation.

What excipients are most important for AGGRASTAT product development?

Buffer system

The citrate and citric acid system controls the product pH and supports chemical stability. A reformulator should evaluate:

• pH drift during long-term and accelerated storage;
• tirofiban degradation products;
• compatibility with infusion tubing and administration sets;
• interaction with common hospital co-infusions;
• precipitation or haze after dilution;
• container-closure extractables and leachables.

A modified buffer system could become commercially relevant if it improves shelf life, reduces degradation, or supports a more concentrated product. A mere substitution of citrate with another pharmaceutically acceptable buffer would usually have weak patent value without unexpected performance data.

Sodium chloride

Sodium chloride provides tonicity and contributes to the ionic environment of the solution. It also affects dilution behavior, osmolality, and compatibility with hospital infusion protocols.

Potential development options include:

• lower-volume concentrated products;
• reduced-sodium presentations for selected hospital protocols;
• pre-diluted products with standard infusion-bag osmolality;
• ready-to-administer syringes for bolus dosing.

A lower-sodium claim would require careful clinical and regulatory positioning. Tirofiban is administered in acute-care settings where infusion volume and sodium load may matter, but the commercial value depends on whether pharmacy and cardiology departments perceive a meaningful operational benefit.

Water for injection and solution quality

Because AGGRASTAT is a sterile parenteral product, the manufacturing process and water system are central to quality. A commercial entrant must control:

• bioburden and endotoxin;
• visible and subvisible particles;
• oxygen exposure;
• light exposure;
• container-closure integrity;
• fill-volume accuracy;
• sterilization validation;
• particulate shedding from bags, vials, or syringes.

These attributes may not create composition patents, but they can determine hospital acceptance, product recalls, and contract-manufacturing economics.

What formulations are protected by AGGRASTAT patents?

AGGRASTAT was first approved by the FDA in 1998 under NDA 020862. The original product’s conventional aqueous formulation has been commercially available for many years, and its principal exclusivity period has expired. [1,3]

The practical IP position is therefore different from that of a recently launched branded drug:

IP category	Commercial relevance for AGGRASTAT
Original tirofiban compound patents	Expired or commercially exhausted
Original aqueous formulation	Limited current exclusivity value
Premixed infusion bags	Potential presentation and process differentiation
Concentrated formulations	Possible formulation and method-of-use claims
Stability-enhanced products	Potential patent value if supported by comparative data
Container-closure systems	Possible device or packaging protection
Manufacturing processes	Possible trade-secret and process-control value
Hospital-use workflow	Primarily commercial, not patent-based

No commercial strategy should assume that a reformulated tirofiban product has meaningful freedom-to-operate solely because the original AGGRASTAT patents have expired. Later patents, third-party formulation rights, packaging claims, and manufacturing agreements can affect a specific product configuration.

The most defensible formulation claims would likely require a defined combination of:

1. tirofiban concentration;
2. buffer composition;
3. pH range;
4. container material;
5. oxygen or light-control condition;
6. storage period;
7. demonstrated impurity or potency result.

Broad claims covering tirofiban in water with standard tonicity agents are vulnerable to validity and obviousness challenges.

When does AGGRASTAT lose exclusivity?

AGGRASTAT has already lost the market exclusivity associated with its original approval. Tirofiban products can be developed through abbreviated or hybrid regulatory pathways, subject to current FDA requirements and the specific reference-product listing.

The commercial question is not whether AGGRASTAT has remaining new-drug exclusivity. It is whether a competing product can obtain approval with a commercially useful presentation and achieve hospital formulary adoption.

The main regulatory routes are:

• ANDA for a therapeutically equivalent generic product;
• 505(b)(2) application for a materially different presentation or formulation;
• institutional or regional supply arrangements using an approved injectable product;
• contract-manufactured private-label products.

A conventional generic premixed solution is likely to face price competition. A 505(b)(2) strategy could be more attractive if the product materially changes concentration, administration volume, packaging, or storage conditions.

What is the Orange Book status of AGGRASTAT?

The FDA Orange Book identifies approved drug products, patents submitted by NDA holders, exclusivity information, and therapeutic-equivalence evaluations. AGGRASTAT is associated with NDA 020862. [2]

For a competitor, the relevant diligence questions are:

• whether the reference listing has any unexpired patent entries;
• whether listed patents cover the formulation, method of use, or product presentation;
• whether an ANDA requires Paragraph IV certification;
• whether a 30-month stay or patent litigation risk applies;
• whether the proposed product can be approved with a Section viii statement for a non-patented use.

Because tirofiban’s original exclusivity period is long expired, the principal risk is unlikely to come from basic active-ingredient exclusivity. It is more likely to arise from a later formulation, packaging, manufacturing, or use patent, if any such rights remain listed and enforceable.

Which companies are challenging or competing with AGGRASTAT?

The competitive landscape includes the branded product, generic tirofiban products, and alternative antiplatelet therapies. Relevant competitors include:

• generic tirofiban hydrochloride injection manufacturers;
• Medicure Pharma, associated with AGGRASTAT commercialization;
• manufacturers of eptifibatide, another intravenous glycoprotein IIb/IIIa inhibitor;
• manufacturers of cangrelor, an intravenous P2Y12 inhibitor;
• oral P2Y12 inhibitors such as clopidogrel, prasugrel, and ticagrelor.

Tirofiban competes on clinical protocol, onset and reversibility, hospital familiarity, price, and supply availability. The product is used in a narrower setting than oral antiplatelet drugs, so market share depends heavily on PCI-center protocols and acute-care procurement.

A generic entrant does not need to displace all competing antiplatelet agents. It can target hospitals that already use tirofiban and offer a lower acquisition cost or a more convenient administration format.

What excipient strategies can create commercial differentiation?

Ready-to-use premixed bags

Premixed bags eliminate pharmacy compounding and reduce preparation steps. Their value is operational:

• lower manipulation burden;
• reduced calculation errors;
• shorter time to administration;
• lower sterile-compounding exposure;
• simplified emergency-department and cath-lab inventory.

A manufacturer can differentiate through bag sizes, concentration options, overwrap design, and shelf life. The strongest commercial case is a product that matches existing dosing protocols without requiring dilution.

Concentrated bolus or syringe presentations

A concentrated format can reduce the volume required for bolus administration. Potential presentations include:

• prefilled syringes;
• ready-to-use vials;
• cartridge systems;
• small-volume bags;
• dual-format kits containing bolus and infusion components.

The commercial opportunity depends on whether the FDA-approved dosing regimen and labeling support the presentation. A syringe product also creates device, sterility, dose-accuracy, and human-factors requirements.

Extended room-temperature stability

Hospitals value products that tolerate storage outside refrigerated conditions, particularly in emergency departments, catheterization laboratories, and transport settings. A stability program should assess:

• potency;
• related substances;
• pH;
• appearance;
• particulate matter;
• container integrity;
• microbial integrity;
• compatibility after dilution.

An extended-storage claim can support a 505(b)(2) strategy or a product-specific patent if the formulation produces a non-obvious technical result. It can also improve distribution economics by reducing cold-chain dependence.

Improved container-closure systems

Polyolefin bags, multilayer films, glass vials, cyclic olefin polymer syringes, and other materials can affect adsorption, permeation, extractables, and particulate performance. A differentiated package may offer:

• lower oxygen transmission;
• reduced light exposure;
• lower extractables;
• improved port integrity;
• clearer visual inspection;
• better pump compatibility.

Packaging claims may be more durable than simple excipient substitutions, particularly when linked to a measurable stability or usability advantage.

Low-particulate and low-sorption systems

Tirofiban products must maintain dose delivery through tubing, connectors, filters, and infusion pumps. Evaluation should include adsorption to administration materials and recovery at the end of the infusion line.

A product with validated low-sorption behavior could have value in pediatric, low-dose, or low-volume settings, although the principal AGGRASTAT market is adult acute-care medicine.

How strong is the patent estate for an AGGRASTAT reformulation?

The patent strength of a new tirofiban formulation would depend on technical specificity and comparative evidence.

Claim type	Expected commercial defensibility
Tirofiban plus water	Weak
Tirofiban plus sodium chloride	Weak to moderate
Defined citrate buffer and pH range	Moderate if stability benefit is demonstrated
Concentrated product with defined impurity profile	Moderate to strong
Specific container and oxygen-control system	Moderate
Prefilled syringe with device features	Moderate, often split between drug and device rights
Stability improvement supported by unexpected data	Stronger
Manufacturing process with narrow critical parameters	Moderate, often better protected as know-how
Broad method-of-use claim for platelet inhibition	Weak if treatment use is established

The most valuable protection may be a layered portfolio:

1. formulation patent;
2. container-closure or device patent;
3. process patent;
4. trademark and trade dress;
5. confidential manufacturing know-how;
6. supply and distribution contracts.

Patent protection alone is unlikely to prevent generic substitution. A company needs a cost and service advantage that hospitals can recognize in purchasing decisions.

What manufacturing and IP barriers affect commercial entry?

Sterile injectable manufacturing is the main operational barrier. A new entrant needs validated aseptic processing, reliable active-ingredient supply, and a container system that performs through the labeled shelf life.

Key barriers include:

• qualified tirofiban hydrochloride API supply;
• sterile fill-finish capacity;
• aseptic process validation;
• extractables and leachables testing;
• stability data across intended markets;
• serialization and aggregation requirements;
• shortage-risk management;
• FDA inspection readiness;
• compatibility data for infusion systems.

API sourcing can be especially important for a low-margin generic. If several manufacturers use the same limited API suppliers, a supply interruption can create a commercial advantage for a company with redundant sourcing.

Trade secrets may offer greater practical value than patents in areas such as impurity control, oxygen management, filling parameters, and terminal sterilization limitations. These advantages are difficult for competitors to identify from the finished product.

What licensing deals could support an AGGRASTAT opportunity?

Potential licensing structures include:

• exclusive regional commercialization rights;
• an ANDA or 505(b)(2) asset license;
• a formulation and packaging technology license;
• a contract-manufacturing agreement with minimum-volume commitments;
• a co-development deal for prefilled syringes;
• a hospital-distribution partnership;
• a private-label supply agreement.

A licensee should distinguish rights to the drug product from rights to the brand, regulatory dossier, manufacturing process, and patents. The transaction should also address shortages, API substitution, change-control authority, pharmacovigilance, recalls, and regulatory correspondence.

The best licensing target is a product with a regulatory pathway already defined and a manufacturing platform that can support other sterile injectables. A standalone tirofiban asset may have limited value unless it includes a differentiated presentation or a strategic hospital channel.

What generic launch scenarios exist for AGGRASTAT?

Standard generic launch

A standard tirofiban injection can compete on acquisition price. This is the lowest-risk regulatory strategy but usually has the weakest margin profile.

Premium ready-to-use launch

A premixed bag or syringe can support a higher price if it reduces preparation time, waste, and medication-error risk. Hospital value-analysis committees will require evidence that the operational savings exceed the price premium.

Regional shortage-response launch

A manufacturer can focus on health systems, group purchasing organizations, or regions affected by supply interruptions. Reliability, inventory availability, and rapid replenishment can be more important than nominal unit price.

Multi-product portfolio launch

Tirofiban can be bundled with other cardiovascular injectables, emergency medicines, or cath-lab products. Portfolio selling can lower distribution costs and improve formulary access.

What is the revenue exposure for AGGRASTAT?

Revenue exposure is driven by the number of PCI centers using tirofiban, dosing frequency, generic price erosion, and the share of demand captured by premixed products. The market is narrower than the overall antiplatelet market because tirofiban is an acute-care intravenous product.

The main revenue risks are:

• substitution by eptifibatide or cangrelor;
• declining use of glycoprotein IIb/IIIa inhibitors;
• hospital conversion to lower-cost generics;
• procurement consolidation;
• tender-based price reductions;
• supply interruptions;
• clinical protocol changes.

The main revenue opportunities are:

• premium pricing for labor-saving presentations;
• contracts with integrated delivery networks;
• cath-lab stocking programs;
• dependable supply during shortages;
• international markets with limited local competition;
• private-label or co-branded products.

How does AGGRASTAT compare with eptifibatide and cangrelor?

Factor	Tirofiban	Eptifibatide	Cangrelor
Drug class	GP IIb/IIIa inhibitor	GP IIb/IIIa inhibitor	P2Y12 inhibitor
Administration	IV bolus and infusion	IV bolus and infusion	IV bolus and infusion
Main commercial advantage	Established use and generic potential	Established PCI use	Rapid, reversible platelet inhibition
Excipient opportunity	Premixed bags, concentration, syringes	Similar sterile-injectable opportunities	Formulation and stability may be more differentiated
Generic pressure	High	High to moderate, depending on market	Lower than older generic products
Procurement focus	Cost, availability, workflow	Cost, availability, workflow	Clinical differentiation and price

Tirofiban has a clearer low-cost generic opportunity than cangrelor. Its commercial weakness is that a conventional injectable generic can become commoditized quickly. Product presentation and supply reliability are therefore central to any investment thesis.

Key Takeaways

• AGGRASTAT contains tirofiban hydrochloride in a simple buffered aqueous injectable formulation.
• The original product’s new-drug exclusivity has expired, so the market is open to generic and differentiated injectable competition.
• The highest-value excipient opportunities involve citrate-buffer optimization, concentrated dosing, stability, and container compatibility.
• Simple excipient substitutions are unlikely to support strong patent protection without unexpected technical results.
• Premixed bags and prefilled syringes can create commercial value by reducing pharmacy handling and administration time.
• Sterile manufacturing, API supply, container performance, and hospital distribution are major entry barriers.
• A standard generic is likely to face price erosion. A ready-to-use or shortage-resilient product can support better economics.
• Any transaction should review current Orange Book listings, Paragraph IV exposure, formulation patents, device rights, and regional regulatory status before closing.

FAQs About AGGRASTAT Excipient and Commercial Strategy

Is AGGRASTAT preservative-free?

Yes. AGGRASTAT is supplied as a sterile parenteral solution without a conventional antimicrobial preservative. [1]

Can tirofiban be developed as a prefilled syringe?

Yes, but the presentation would require evaluation of syringe-material compatibility, dose accuracy, sterility assurance, extractables and leachables, stability, and administration-device requirements.

Is a citrate-buffered tirofiban formulation patentable?

Potentially, but a patent would need technically specific claims and evidence of a meaningful advantage, such as improved stability, reduced impurities, or better container compatibility.

Is a 505(b)(2) pathway commercially attractive for tirofiban?

It can be attractive for a materially differentiated presentation, including a concentrated product, prefilled syringe, or formulation with a different storage profile. A conventional copy is more likely to fit an ANDA strategy.

What is the largest commercial risk for a new AGGRASTAT competitor?

The largest risk is commoditization of a conventional injectable product combined with hospital purchasing pressure, clinical substitution, and the need for reliable sterile manufacturing.